## Mireia Casulleras

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3783952/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunctionâ€associated fatty liver disease. Hepatology, 2023, 77, 1303-1318.	7.3	10
2	Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure. Journal of Hepatology, 2022, 76, 93-106.	3.7	51
3	Albumin Lipidomics Reveals Meaningful Compositional Changes in Advanced Cirrhosis and Its Potential to Promote Inflammation Resolution. Hepatology Communications, 2022, 6, 1443-1456.	4.3	6
4	Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators. Frontiers in Immunology, 2022, 13, 842996.	4.8	11
5	Albumin protects the liver from tumor necrosis factor αâ€induced immunopathology. FASEB Journal, 2021, 35, e21365.	0.5	15
6	Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 75, 1116-1127.	3.7	31
7	Proresolving lipid mediators and liver disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 159023.	2.4	11
8	Mitochondrial Dysfunction in Advanced Liver Disease: Emerging Concepts. Frontiers in Molecular Biosciences, 2021, 8, 772174.	3.5	9
9	Anti-Inflammatory and Proresolving Effects of the Omega-6 Polyunsaturated Fatty Acid Adrenic Acid. Journal of Immunology, 2020, 205, 2840-2849.	0.8	33
10	Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis. Science Translational Medicine, 2020, 12, .	12.4	47
11	Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28263-28274.	7.1	31
12	Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. Cells, 2020, 9, 2632.	4.1	65
13	Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis. Journal of Hepatology, 2020, 73, 817-828.	3.7	48
14	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology, 2019, 157, 149-162.	1.3	178
15	Leukocytes from obese individuals exhibit an impaired SPM signature. FASEB Journal, 2019, 33, 7072-7083.	0.5	45
16	Orchestration of Tryptophanâ€Kynurenine Pathway, Acute Decompensation, and Acuteâ€onâ€Chronic Liver Failure in Cirrhosis. Hepatology, 2019, 69, 1686-1701.	7.3	80
17	The soluble guanylate cyclase stimulator IWâ€1973 prevents inflammation and fibrosis in experimental nonâ€alcoholic steatohepatitis. British Journal of Pharmacology, 2018, 175, 953-967.	5.4	53
18	Oxidized Albumin Triggers a Cytokine Storm in Leukocytes Through P38 Mitogenâ€Activated Protein Kinase: Role in Systemic Inflammation in Decompensated Cirrhosis. Hepatology, 2018, 68, 1937-1952.	7.3	70

MIREIA CASULLERAS

#	Article	IF	CITATIONS
19	Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome. Journal of Leukocyte Biology, 2018, 105, 25-36.	3.3	72
20	Pro-resolving actions of SPM in adipose tissue biology. Molecular Aspects of Medicine, 2017, 58, 83-92.	6.4	33
21	The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxiaâ€induced endoplasmic reticulum stress. FASEB Journal, 2017, 31, 5384-5398.	0.5	56
22	Association of a variant in the gene encoding for ERV1/ChemR23 with reduced inflammation in visceral adipose tissue from morbidly obese individuals. Scientific Reports, 2017, 7, 15724.	3.3	27
23	Polymorphisms in the ILâ€I gene cluster influence systemic inflammation in patients at risk for acuteâ€onâ€chronic liver failure. Hepatology, 2017, 65, 202-216.	7.3	39
24	Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue. Journal of Immunology, 2016, 197, 3360-3370.	0.8	87
25	Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases. European Journal of Pharmacology, 2016, 785, 133-143.	3.5	73
26	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
27	Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction. Molecular and Cellular Endocrinology, 2016, 419, 44-59.	3.2	64
28	Prostaglandin E2 Exerts Multiple Regulatory Actions on Human Obese Adipose Tissue Remodeling, Inflammation, Adaptive Thermogenesis and Lipolysis. PLoS ONE, 2016, 11, e0153751.	2.5	98
29	Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 536-541.	7.1	185
30	Molecular interplay between $\hat{l}$ "5/ $\hat{l}$ "6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut, 2014, 63, 344-355.	12.1	107
31	Resolvin D1 primes the resolution process initiated by calorie restriction in obesityâ€induced steatohepatitis. FASEB Journal, 2014, 28, 836-848.	0.5	97
32	Coordinate Functional Regulation between Microsomal Prostaglandin E Synthase-1 (mPGES-1) and Peroxisome Proliferator-activated Receptor γ (PPARγ) in the Conversion of White-to-brown Adipocytes. Journal of Biological Chemistry, 2013, 288, 28230-28242.	3.4	72
33	Cell-specific PPARÎ <sup>3</sup> deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. Journal of Hepatology, 2013, 59, 1045-1053.	3.7	91
34	Resolution of inflammation in obesity-induced liver disease. Frontiers in Immunology, 2012, 3, 257.	4.8	67
35	New insights into the role of macrophages in adipose tissue inflammation and fatty liver disease: modulation by endogenous omega-3 fatty acid-derived lipid mediators. Frontiers in Immunology, 2011, 2, 49.	4.8	40
36	Resolvin D1 and Its Precursor Docosahexaenoic Acid Promote Resolution of Adipose Tissue Inflammation by Eliciting Macrophage Polarization toward an M2-Like Phenotype. Journal of Immunology, 2011, 187, 5408-5418.	0.8	360

#	Article	IF	CITATIONS
37	Role for PPARγ in obesityâ€induced hepatic steatosis as determined by hepatocyte―and macrophageâ€specific conditional knockouts. FASEB Journal, 2011, 25, 2538-2550.	0.5	325
38	Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. Hepatology, 2010, 52, 1980-1991.	7.3	59